2seventy bio, Inc.
NASDAQ: TSVT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William D. Baird III,
- Employees
- 65
- Headquarters
- Cambridge, United States
- IPO year
- 2021
- Market cap
- $266.1M
- Website
- https://www.2seventybio.com
Loading TSVT…
Loading profile data…Frequently asked questions about TSVT
What does 2seventy bio, Inc. (TSVT) do?
2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidate...
Where does TSVT trade?
2seventy bio, Inc. (TSVT) trades on the NASDAQ Global Select.
What sector is TSVT in?
2seventy bio, Inc. (TSVT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of 2seventy bio, Inc.?
William D. Baird III, is the chief executive officer of 2seventy bio, Inc. (TSVT).
Where is 2seventy bio, Inc. headquartered?
2seventy bio, Inc. is headquartered in United States.
Does TSVT pay a dividend?
2seventy bio, Inc. (TSVT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TSVT go public?
2seventy bio, Inc. (TSVT) completed its initial public offering in 2021.